Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno
Y
Yongkai Lu
(Yongkai Lu, MD, Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China)
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 44, Issue 18
Published
June 20, 2026
Pages
1745-1746
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (1)
Y
Yongkai Lu
Yongkai Lu, MD, Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001